An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
about
Burkitt lymphoma in adolescents and young adults: management challenges.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Bilateral subdural hygromas following administration of intrathecal methotrexate chemotherapy.Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.Primary intestinal non-Hodgkin's lymphoma: a clinicopathologic analysis of 81 patientsA Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.Primary cardiac burkitt lymphoma presenting with abdominal pain.Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.Primary Gastric Burkitt's Lymphoma.Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis.AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Spinal Burkitt's Lymphoma Mimicking Dumbbell Shape Neurogenic Tumor: A Case Report and Review of the Literature.Central nervous system-directed preventative therapy in adults with lymphoma.Successful Management of Jejunal Perforation in Burkitt's Lymphoma: A Case Report.Treatment of Burkitt lymphoma in adults.Update on the therapy of highly aggressive non-Hodgkin's lymphoma.Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchCombined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomasA prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.Low-intensity therapy in adults with Burkitt's lymphoma.Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma.Burkitt lymphoma in adults.Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors.Molecular profiling of aggressive lymphomasThe role of hematopoietic SCT in adult Burkitt lymphoma.Therapeutic approaches to haematological malignancies in adolescents and young adults.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Treating Burkitt Lymphoma in Adults.Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.Clinical management of HIV-associated hematologic malignancies.
P2860
Q30238965-1A8563A0-8C23-40AB-9095-303298AF5B01Q33411059-31459BCD-3258-4D93-BBB1-9BA81CAE36A2Q33423067-BB2BAA49-2802-48A8-A79C-223A1F8DDD74Q33441858-B87B0EE7-C4F3-4028-AE10-4BEA30569FD0Q33583302-0C5735A2-246A-4D2B-97F1-C7632F73C0BEQ34018599-7176DE64-5120-440B-AA82-53FBD5C64963Q34093299-3E5B153C-9C37-4E86-83F4-474B73C2611AQ34347222-DDDF0FD1-705A-4E02-BA2D-541DD9712B1CQ34522797-7CF50B83-A98E-4E0A-8EA3-01F1112693A2Q34560650-F6AB72C8-80B5-4D57-8F8B-19A5EEF62BC5Q34606414-7DAB9EE2-887E-469F-A6EE-7C151D911F55Q34627112-C54D9A3F-291C-44D5-B7EB-5F584A14C856Q34760470-32C9D68F-40B7-41A6-A79A-2510E749AED6Q35384536-D403C695-8E7A-421F-92DE-DEF1E7882861Q35429833-E18BBAF7-2A15-45C1-B9ED-8A79A75432B3Q35794300-59C54482-BBD3-4D76-A13F-7A51D954F0F1Q35836856-A6E5F469-9A0E-4068-9066-E689233A7F52Q35930640-B88FE205-B9D6-4944-9B3C-9AACC68CF8A4Q36215259-6C15CC90-444B-4B5D-ACCA-3466D4DA54C0Q36262219-4E1672DC-3743-46CF-AC62-A3C93AB31B0CQ36277530-0EA31D15-E014-4CD1-B9BC-02273E6ECC8FQ36407453-A1F2CA3A-9FAF-45B9-812F-7D893B7DC68FQ36521840-804196D7-A06B-4AC8-B229-4C5D1D586CFFQ36557201-07D54605-5BB5-4E31-AF61-56270D6EE67EQ36761564-E03D55EF-ED7D-4770-96B1-0C7D26C1509FQ36868708-A1BFB342-234F-4BD6-A256-65C3B645B1B8Q37476684-C8C280A9-00D8-4E98-B397-BD0558FAB989Q37511989-2E0FC5C9-589F-4754-954D-AF96E1E0DA9CQ37706621-3AEF8FCB-089F-49F6-91BF-195B1D9CEACFQ37718297-9A3CCAE1-D65E-4579-9261-4C2D2AAC306BQ37719073-066B5D21-9007-4B9E-B809-4266AE148B90Q37933440-C7807B61-2CF1-4EDE-ACDB-742281959B37Q37963986-669BA727-3527-4993-99A8-306CA7A7FBA0Q37970680-D4D33DF3-BA3F-4B54-83F4-C16A8029F9C0Q38031733-3B3AEB1D-1B92-4680-B434-0509E2DA6887Q38134399-D41551C7-B96B-4762-B7C9-97DF575DCF58Q38242272-6D364604-7B84-482F-ACEA-C485D477FD6BQ38503297-B5E6DA08-37B5-439B-827D-97CCED05EF03Q38620631-05A7BD5E-A048-4B16-8B6D-112133059E78Q38664912-FE2431DE-E2C6-49C9-B3CA-C63506038FBD
P2860
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
An international evaluation of ...... dom Lymphoma Group LY06 study.
@ast
An international evaluation of ...... dom Lymphoma Group LY06 study.
@en
An international evaluation of ...... dom Lymphoma Group LY06 study.
@nl
type
label
An international evaluation of ...... dom Lymphoma Group LY06 study.
@ast
An international evaluation of ...... dom Lymphoma Group LY06 study.
@en
An international evaluation of ...... dom Lymphoma Group LY06 study.
@nl
prefLabel
An international evaluation of ...... dom Lymphoma Group LY06 study.
@ast
An international evaluation of ...... dom Lymphoma Group LY06 study.
@en
An international evaluation of ...... dom Lymphoma Group LY06 study.
@nl
P2093
P2860
P356
P1433
P1476
An international evaluation of ...... dom Lymphoma Group LY06 study.
@en
P2093
C Guarnaccia
C S Hatton
J McKendrick
N Pescosta
S P Stenning
UKLG LY06 collaborators
P2860
P304
P356
10.1093/ANNONC/MDF253
P577
2002-08-01T00:00:00Z